Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal model

NewsGuard 100/100 Score

The repeated zoonotic spillovers of α- and β-coronaviruses (CoV) have significantly increased morbidity and mortality worldwide. The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spillover is likely from a bat or a pangolin. This highly infectious virus has resulted in the coronavirus disease 2019 (COVID-19) pandemic, claiming more than 6.64 million lives worldwide.

Study: Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge. Image Credit: thinkhubstudio / ShutterstockStudy: Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge. Image Credit: thinkhubstudio / Shutterstock


SARS-CoV-2 contains the spike (S) protein, which comprises two subunits, namely, S1 and S2. The S1 subunit binds with the host's angiotensin-converting enzyme 2 (ACE2) receptor, while the S2 subunit promotes membrane fusion to establish viral infection. Hence, the S protein is the main target of neutralizing antibodies (nAbs).

The S1 subunit contains a receptor-binding domain (RBD) and an N-terminal domain (NTD), and two S1 subdomains (SD1 and SD2). The RBD domain is responsible for over 90% of neutralizing activity, elucidated from studying COVID-19 convalescent patients and vaccinated individuals. Interestingly, RBD monomer, dimer, and trimer were observed to trigger potent Ab responses. In addition, self-assembling multivalent RBD nanoparticles exhibited induction of significant immune responses.

The outbreaks of SARS-CoV-2 variants have been driven by waning immunity, immune evasion, and increased infectiousness. Some of the variants, such as the Delta and Omicron strains, are less vulnerable to the RBD-directed antibodies. However, after the administration of the third dose of the COVID-19 vaccine, lower rates of infection and severe illness were recorded. 

Immunological imprinting against strain-specific antigens could cause overspecialization of immunodominant B cells with limited breadth. However, heterologous RBDs on nanoparticles were more advantageous than cross-reactive B cells, particularly for inducing broader Ab responses. Nevertheless, a key drawback of mosaic nanoparticle platforms has been their dependence on stochastic assembly, where they use a mixture of antigen-fused tags to assemble mosaic nanoparticles. It is exceptionally challenging to co-display heterologous RBDs in mass production, as a uniform distribution of antigens on nanoparticles is difficult.

A New Study

A recent PNAS journal study has sought to address the above-stated drawback and developed a new strategy that involves a self-assembling scaffold of proliferating cell nuclear antigen (PCNA). This technique can develop nanoparticles containing evenly incorporated heterotypic antigens.

PCNA is a protein that infolds DNA as a processivity factor. A hyperthermophilic archaea, namely, Saccharolobus solfataricus, possesses a heterotrimeric PCNA, which was selected as a scaffold with three subunits (PCNA1, PCNA2, and PCNA3).

Despite their low sequence similarity, PCNA subunits have a similar structure, contain around 250 amino acids, and are arranged in a sequential manner. PCNA1 and PCNA2 combine and recruit PCNA3 to form a heterotrimer whose dissociation constants are between micromolar and nanomolar ranges.

The current study selected six RBD-SD1s derived from α- and β- coronaviruses associated with zoonotic infection. These heterologous RBD-SD1s were fused at the termini of PCNA1, PCNA2, and PCNA3, which self-assemble in a precise order to form 6RBD-np. Characterization of 6RBD-np revealed a ring-shaped disk structure with six protruding RBD-SD1s. The nanoparticle's structure resembled jewels in a crown of around 40 nm.

The β-CoVs, hCoV HKU1, SARS-CoV, SARS-CoV-2, and MERS-CoV, share a five-stranded antiparallel β-sheet and extended loops of receptor-binding motifs, while the α-CoVs, hCoVs 229E and NL63 share a β-sandwich of three-stranded β-sheets. When superimposed, the six RBD structures share a central β-sheet with different arrangements of extended loops.

Study Findings

Based on antigenic characterization, six heterologous antigens were found to be evenly distributed on 6RBD-np. This finding highlighted the advantages of using the PCNA subunits for developing mosaic multivalent antigens compared to previously used stochastic assembly platforms.

Notably, BALB/c mice administered with 6RBD-np exhibited elevated levels of Ab titers for each antigen in post-boost sera. The hACE2 transgenic mice, after booster vaccination with 6RBD-np, demonstrated a protected immune response against the wild-type (WT) SARS-CoV-2 and Delta challenges. Importantly, this treated group only exhibited 100% survival rates among the antigen group.

Pseudovirus-based and authentic virus-based neutralization assays indicated that 6RBD-np induced significantly high nAb titers, which had broad serum neutralization ability. In the challenged sera, both S-PCNA1 and 6RBD-np groups exhibited significant Ab titers against the RBDs derived from SARS-CoV and SARS-CoV-2. 

Although the 6RBD-np group exhibited high Ab titers against the RBDs of hCoVs HKU1 and MERS, the S-2P and 6RBD-np groups demonstrated high titers against 229E and NL63. Since the high levels of Abs in the S-2P group against 229E and NL63 RBDs were only found in the WT challenge, they suitably indicate the importance of antigen size. This is because S-2P and 6RBD-np were among the largest-sized studied antigens.


The newly developed mosaic 6RBD-np possesses five β-CoV RBDs and an α-CoV RBD that induced potent Ab response in sera against the RBDs for not only α- and β-CoV but also hCoV NL63 RBD. Importantly, the 6RBD-np also exhibited significant potency against bat CoV RaTG13 and Omicron (BA.1) variant. The current study revealed that the 6RBD-np plays a crucial role in achieving a broad-spectrum immunity based on conformationally conserved epitopes.

Journal reference:
Dr. Priyom Bose

Written by

Dr. Priyom Bose

Priyom holds a Ph.D. in Plant Biology and Biotechnology from the University of Madras, India. She is an active researcher and an experienced science writer. Priyom has also co-authored several original research articles that have been published in reputed peer-reviewed journals. She is also an avid reader and an amateur photographer.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Bose, Priyom. (2023, January 24). Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal model. News-Medical. Retrieved on April 23, 2024 from

  • MLA

    Bose, Priyom. "Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal model". News-Medical. 23 April 2024. <>.

  • Chicago

    Bose, Priyom. "Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal model". News-Medical. (accessed April 23, 2024).

  • Harvard

    Bose, Priyom. 2023. Mosaic RBD nanoparticles offer 100% protection against SARS-CoV-2 in animal model. News-Medical, viewed 23 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
COVID-19 linked to higher dementia risk in older adults, study finds